Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer.

摘要: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. At diagnosis, half patients are over 70 years age, and most present with advanced disease, for which chemotherapy recommended as first-line treatment. However, benefit from such therapy modest it at times poorly tolerated. The discovery epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has significantly impacted treatment EGFR mutation-positive NSCLC. These novel agents demonstrate efficacy a favorably mild toxicity profile. Despite limited data in elderly patients, largest subpopulation NSCLC, EGFR-TKIs considered standard care EGFR-positive disease elderly. In this review, we seek to compile available about use hope better understand its role major yet, underrepresented, group patients.